Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

Login or register to view PDF.
Abstract

Abstract

Background
Increased dietary cholesterol intake is associated with atherosclerosis. Atherosclerosis development requires a lipid and an inflammatory component. It is unclear where and how the inflammatory component develops. To assess the role of the liver in the evolution of inflammation, we treated ApoE*3Leiden mice with cholesterol-free (Con), low (LC; 0.25%) and high (HC; 1%) cholesterol diets, scored early atherosclerosis and profiled the (patho)physiological state of the liver using novel whole-genome and metabolome technologies.

References
  1. Braunwald E: Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
  2. Blum CB, Levy RI: Role of dietary intervention in the primary prevention of coronary heart disease. Individuals with highnormal or elevated serum cholesterol levels should be placed on cholesterol-lowering diets. Cardiology 1987, 74:2-21.
  3. Steinberg D: Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol Nutr Food Res 2005, 49:995-998.
  4. Steinberg D: Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
  5. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-10.
  6. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
  7. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, Kooistra T: Effect of low dose atorvastatin versus dietinduced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2005, 25:161-167.
  8. Kleemann R, Kooistra T: HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:441-453.
  9. Rein D, Schijlen E, Kooistra T, Herbers K, Verschuren L, Hall R, Sonnewald U, Bovy A, Kleemann R: Transgenic flavonoid tomato intake reduces C-reactive protein in human C-reactive protein transgenic mice more than wild-type tomato. J Nutr 2006, 136:2331-2337.
  10. Tannock LR, O'Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, Kahn SE, Chait A: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005, 111:3058-3062.
  11. Groot PH, van Vlijmen BJ, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, Havekes LM: Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996, 16:926-933.
  12. Zadelaar S, Kleemann R, Verschuren L, de Vries-van der Weij , van der HJ, Princen HM, Kooistra T: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
  13. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, Van Der BH, HogenEsch H, Frants RR, Hofker MH, Havekes LM: Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994, 93:1403-1410.
  14. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM: Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003, 108:1368-1374.
  15. Lutgens E, Daemen M, Kockx M, Doevendans P, Hofker M, Havekes L, Wellens H, de Muinck ED: Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation 1999, 99:276-283.
  16. Shimano H: Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc Med 2000, 10:275-278.
  17. Zaima N, Sugawara T, Goto D, Hirata T: Trans geometric isomers of EPA decrease LXRalpha-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1beta. J Lipid Res 2006, 47:2712-2717.
  18. Tous M, Ferre N, Rull A, Marsillach J, Coll B, onso-Villaverde C, Camps J, Joven J: Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun 2006, 340:1078-1084.
  19. Grothusen C, Bley S, Selle T, Luchtefeld M, Grote K, Tietge UJ, Drexler H, Schieffer B: Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005, 182:57-69.
  20. Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach F: Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptordeficient mice. Circulation 2003, 107:1033-1039.
  21. Tous M, Ferre N, Camps J, Riu F, Joven J: Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem 2005, 268:53-58.
  22. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K: Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 2003, 278:42774-42784.
  23. Recinos A III, Carr BK, Bartos DB, Boldogh I, Carmical JR, Belalcazar LM, Brasier AR: Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiol Genomics 2004, 19:131-142.
  24. Zabalawi M, Bhat S, Loughlin T, Thomas MJ, Alexander E, Cline M, Bullock B, Willingham M, Sorci-Thomas MG: Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am J Pathol 2003, 163:1201-1213.
  25. Fischer-Frohlich CL, Lauchart W: Expanded criteria liver donors (ECD): effect of cumulative risks. Ann Transplant 2006, 11:38-42.
  26. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb H: Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann NY Acad Sci 2006, 1084:30-48.
  27. Kooistra T, Verschuren L, de Vries-van der Weij , Koenig W, Toet K, Princen HM, Kleemann R: Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 2006, 26:2322-2330.
  28. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
  29. Shoelson SE, Lee J, Yuan M: Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S49-S52.
  30. Jaiswal DM, Belsare DK: Effect of salicylate and adrenocorticotropin on the hepatic and serum cholesterol in catfish, Heteropneustes fossilis (Bloch). Acta Biol Med Ger 1976, 35:757-761.
  31. Beynen AC, Buechler KF, van der Molen AJ, Geelen MJ: Inhibition of hepatic lipogenesis by salicylate. Toxicology 1982, 24:33-43.
  32. Prigge WF, Gebhard RL: Oral acetylsalicylic acid induces biliary cholesterol secretion in the rat. Lipids 1997, 32:753-758.
  33. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, Finkelmeier D, Geiger G, Schaefer HE, Schober A, et al.: Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 2006, 184:28-38.
  34. van der Greef J, van der Heijden R, Verheij ER: The role of mass spectrometry in systems biology: data processing and identification strategies in metabolomics. In Advances in Mass Spectrometry Volume 16. Edited by: Ashcroft AE, Brenton G, Monaghan JJ. Amsterdam: Elsevier Science; 2004:145-164.
  35. Jolliffe IT: Principal Component Analysis 2nd edition. Springer Verlag; 2004.
  36. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et al.: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596.
  37. ArrayExpress Database: accession number of dataset: ETABM- 253 [http://www.ebi.ac.uk/arrayexpress]
  38. Verschuren L, Lindeman JH, Bockel JH, Abdul-Hussien H, Kooistra T, Kleemann R: Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal 2005, 7:1195-1202.
  39. BRB ArrayTools [http://linus.nci.nih.gov/BRB-ArrayTools.html]
  40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.